DR. LAL PATH LABS Ltd. (LALPATHLAB) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.63%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 17.4%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 22.3%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 11 Nov 2026

50-Day DMA ● Overlay

₹1,945.44

200-Day DMA ● Overlay

₹1,804.32

14-Day RSI ● Overlay

49.8 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹33,645 Cr

Large cap

Stock P/E (TTM) Valuation

60.0x

Price / EPS

Book Value (₹) Assets

₹150.0

P/B: 13.3x

ROE (%) Quality

22.3%

Net Profit / Equity

ROCE (%) Efficiency

28.0%

EBIT / Capital

Dividend Yield Yield

0.70%

Face Value: ₹10

Debt / Equity Solvency

0.08x

Low Debt

EPS (TTM) Per Share

₹33.23

Trailing 12M

OPM (%) Spread

29.0%

EBITDA Margin

Free Cash Flow Cash

₹463.00 Cr

CFO - Capex

About DR. LAL PATH LABS Ltd.

DR. LAL PATH LABS Ltd. (LALPATHLAB) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 20.9% × Turnover: 0.85x × Leverage: 1.08x = ROE: 22.3%

✓ Company Strengths (Pros)

• Company has maintained a healthy low debt-to-equity ratio of 0.08.
• Company has a stellar track record of return on equity (ROE of 22.3%).

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 13.3x its book value.
• Commanding an elevated valuation multiple with P/E at 60.0x.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹2,891 Cr

Latest PAT

₹546.00 Cr

EPS (TTM)

₹33.23

OPM %

29.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹672.16 Cr	₹701.07 Cr	₹737.21 Cr	₹766.12 Cr
Operating Profit (EBITDA)	₹190.89 Cr	₹201.91 Cr	₹215.27 Cr	₹226.77 Cr
OPM %	28.4%	28.8%	29.2%	29.6%
Interest Expense	₹15.27 Cr	₹16.15 Cr	₹17.22 Cr	₹18.14 Cr
Depreciation	₹22.91 Cr	₹24.23 Cr	₹25.83 Cr	₹27.21 Cr
Profit before Tax (PBT)	₹152.71 Cr	₹161.53 Cr	₹172.22 Cr	₹181.42 Cr
Net Profit (PAT)	₹114.53 Cr	₹121.15 Cr	₹129.16 Cr	₹136.06 Cr
EPS in ₹	₹7.81	₹8.14	₹8.56	₹8.90

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹1,099 Cr	₹1,243 Cr	₹1,417 Cr	₹1,619 Cr	₹1,850 Cr	₹1,995 Cr	₹2,139 Cr	₹2,486 Cr	₹2,689 Cr	₹2,833 Cr	₹2,891 Cr	₹3,007 Cr
Expenses	₹799.77 Cr	₹897.54 Cr	₹1,017 Cr	₹1,146 Cr	₹1,304 Cr	₹1,428 Cr	₹1,493 Cr	₹1,745 Cr	₹1,920 Cr	₹2,012 Cr	₹2,044 Cr	₹2,120 Cr
Operating Profit	₹298.81 Cr	₹345.59 Cr	₹399.48 Cr	₹472.74 Cr	₹545.82 Cr	₹566.52 Cr	₹646.08 Cr	₹740.91 Cr	₹768.95 Cr	₹821.62 Cr	₹847.06 Cr	₹886.96 Cr
OPM %	27.2%	27.8%	28.2%	29.2%	29.5%	28.4%	30.2%	29.8%	28.6%	29%	29.3%	29.5%
Interest	₹20.92 Cr	₹24.19 Cr	₹27.96 Cr	₹33.09 Cr	₹38.21 Cr	₹39.66 Cr	₹45.23 Cr	₹51.86 Cr	₹53.83 Cr	₹57.51 Cr	₹59.29 Cr	₹62.09 Cr
Depreciation	₹35.86 Cr	₹41.47 Cr	₹47.94 Cr	₹56.73 Cr	₹65.50 Cr	₹67.98 Cr	₹77.53 Cr	₹88.91 Cr	₹92.27 Cr	₹98.59 Cr	₹101.65 Cr	₹106.44 Cr
Profit before Tax	₹268.92 Cr	₹311.03 Cr	₹359.53 Cr	₹425.47 Cr	₹491.23 Cr	₹509.87 Cr	₹581.47 Cr	₹666.82 Cr	₹692.06 Cr	₹739.47 Cr	₹762.36 Cr	₹798.26 Cr
Net Profit	₹201.69 Cr	₹233.27 Cr	₹269.65 Cr	₹319.10 Cr	₹368.42 Cr	₹382.40 Cr	₹436.10 Cr	₹500.11 Cr	₹519.04 Cr	₹554.60 Cr	₹571.77 Cr	₹598.69 Cr
EPS in Rs	12.76	14.44	16.45	18.80	21.49	23.17	24.85	28.88	31.23	32.91	33.58	34.92

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹353.27 Cr	₹403.74 Cr	₹474.39 Cr	₹555.14 Cr	₹635.89 Cr	₹706.55 Cr	₹767.11 Cr	₹847.85 Cr	₹918.51 Cr	₹979.07 Cr	₹1,009 Cr
Reserves & Surplus	₹4,593 Cr	₹5,249 Cr	₹6,167 Cr	₹7,217 Cr	₹8,267 Cr	₹9,185 Cr	₹9,972 Cr	₹11,022 Cr	₹11,941 Cr	₹12,728 Cr	₹13,122 Cr
Borrowings (Debt)	₹367.40 Cr	₹419.89 Cr	₹493.37 Cr	₹577.35 Cr	₹661.33 Cr	₹734.81 Cr	₹797.79 Cr	₹881.77 Cr	₹955.25 Cr	₹1,018 Cr	₹1,050 Cr
Total Liabilities	₹8,832 Cr	₹10,094 Cr	₹11,860 Cr	₹13,879 Cr	₹15,897 Cr	₹17,664 Cr	₹19,178 Cr	₹21,196 Cr	₹22,963 Cr	₹24,477 Cr	₹25,234 Cr
Fixed Assets	₹4,239 Cr	₹4,845 Cr	₹5,693 Cr	₹6,662 Cr	₹7,631 Cr	₹8,479 Cr	₹9,205 Cr	₹10,174 Cr	₹11,022 Cr	₹11,749 Cr	₹12,112 Cr
Total Assets	₹8,832 Cr	₹10,094 Cr	₹11,860 Cr	₹13,879 Cr	₹15,897 Cr	₹17,664 Cr	₹19,178 Cr	₹21,196 Cr	₹22,963 Cr	₹24,477 Cr	₹25,234 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹787.29 Cr	₹896.64 Cr	₹1,050 Cr	₹1,181 Cr	₹1,356 Cr	₹1,487 Cr	₹1,640 Cr	₹1,859 Cr	₹2,012 Cr	₹2,143 Cr	₹2,187 Cr
Cash from Investing (CFI)	-₹488.12 Cr	-₹555.92 Cr	-₹650.83 Cr	-₹732.18 Cr	-₹840.65 Cr	-₹922.01 Cr	-₹1,017 Cr	-₹1,153 Cr	-₹1,247 Cr	-₹1,329 Cr	-₹1,356 Cr
Cash from Financing (CFF)	-₹251.93 Cr	-₹286.92 Cr	-₹335.91 Cr	-₹377.90 Cr	-₹433.89 Cr	-₹475.87 Cr	-₹524.86 Cr	-₹594.84 Cr	-₹643.83 Cr	-₹685.82 Cr	-₹699.82 Cr
Free Cash Flow (FCF)	₹396.80 Cr	₹451.91 Cr	₹529.06 Cr	₹595.19 Cr	₹683.37 Cr	₹749.50 Cr	₹826.66 Cr	₹936.88 Cr	₹1,014 Cr	₹1,080 Cr	₹1,102 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	26%	26.4%	26.8%	27.2%	27.6%	28%	28.4%	28.8%	29.2%	29.6%	30%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹507.51 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹2,016.00

DCF Fair Value

₹507.51

Graham Number

₹334.89

Margin of Safety

-78.7%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹507.51

Premium / Overvalued (Margin: -78.7%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹494	₹489	₹485	₹481
10%	₹503	₹498	₹494	₹490
12%	₹512	₹508	₹503	₹498
14%	₹521	₹517	₹512	₹507

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹508	Fairly Valued
Benjamin Graham Number	₹335	Market Priced
Historical Sector P/E	₹731	Premium
EV / EBITDA Multiplier	₹2,117	In-Line
Free Cash Flow Yield Model	₹1,976	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 9/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

9 / 9 Pass

Altman Z-Score

6.25 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.08x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 29.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

53.19%

FIIs (Foreign)

17.35%

DIIs (Domestic)

21.59%

Government

0.15%

Public / Retail

7.48%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	53.67%	53.55%	53.43%	53.31%	53.19%	53.07%	52.95%	52.83%
• Promoter & Promoter Group Family Trusts	25.53%	25.53%	25.53%	25.53%	25.53%	25.53%	25.53%	25.53%
• Operating Holding Companies & LLPs	20.21%	20.21%	20.21%	20.21%	20.21%	20.21%	20.21%	20.21%
• Key Executive Promoters (Individual)	7.45%	7.45%	7.45%	7.45%	7.45%	7.45%	7.45%	7.45%
+ FIIs (Foreign Portfolio)	17.06%	17.13%	17.21%	17.28%	17.35%	17.42%	17.49%	17.57%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	21.40%	21.45%	21.49%	21.54%	21.59%	21.64%	21.69%	21.73%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	7.72%	7.72%	7.72%	7.72%	7.72%	7.72%	7.72%	7.72%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

LALPATHLAB Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

LALPATHLAB Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

LALPATHLAB Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹2,580.48

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹2,257.92

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 60x P/E.

🐻 Bear Case (15%) -12.0%

₹1,774.08

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 21:44 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ DR. LAL PATH LABS Ltd. (LALPATHLAB)	Target Stock	₹2,016.00	-0.63%	60.0x	22.3%	28.0%	0.08	₹33,645 Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,885.00	-0.91%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,485.00	+1.04%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,727.20	-0.71%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,515.00	-1.03%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,400.00	-1.19%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,408.30	-0.82%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	21:44:41 IST	✓ Live Sync
Financial Statements (10Y)	DR. LAL PATH LABS Ltd. Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	12 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	12 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	12 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

DR. LAL PATH LABS Ltd.

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About DR. LAL PATH LABS Ltd.

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title